Latest Factor VIII Stories
WAYNE, N.J., April 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that the U.S.
WAYNE, N.J., April 14, 2011 /PRNewswire/ -- To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia.
BARCELONA, Spain, March 4, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration (FDA) for revised labeling for AlphanateÂ® Antihemophilic Factor/von Willebrand Factor Complex (Human) indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob...
KING OF PRUSSIA, Pa. and MONTREAL, Feb.
GENEVA, Feb. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.
NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice.
Octapharma has been committed to innovative patient care programs since inception and industry partnerships are central to the biopharmaceutical company's mission.
HOBOKEN, N.J., Dec.
KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTraxÂ® System as part of a specially designed software platform for Apple's iPhoneÂ®, iPod touchÂ®, or iPad(TM) devices.
HOBOKEN, N.J., Nov. 8, 2010 /PRNewswire/ -- Octapharma USA is proud to support educational initiatives for von Willebrand Disease (VWD), the most common inherited bleeding disorder, at the 62nd Annual Meeting of the National Hemophilia Foundation (NHF) scheduled for Nov. 11-13 in New Orleans.